Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review
暂无分享,去创建一个
P. Kiely | P. Conaghan | J. Mount | C. Edwards | S. Arthanari | S. Kiri | Jane Barry | Catherine R Mitchell | P. Field | J. Barry
[1] P. Zufferey,et al. FRI0522 Ultrasound-Detected Synovitis May Predict Radiographic Damage Progression in Rheumatoid Arthritis over The Next Five Years – A Prospective Cohort Study Nested in The Swiss Quality Management Program (SCQM) , 2016 .
[2] N. Shadick,et al. THU0090 Association of The Rheumatoid Arthritis Prognostic Factors Anti-Citrullinated Peptide Antibodies, Rheumatoid Factor and Erosions with Disease Activity and Work Productivity , 2016 .
[3] T. Huizinga,et al. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis , 2015, Rheumatology.
[4] H. Nab,et al. Identifying patients with rheumatoid arthritis with moderate disease activity at risk of significant radiographic progression despite methotrexate treatment , 2015, RMD Open.
[5] E. de Miguel,et al. FRI0586 Doppler Ultrasound Better Predicts X-Ray Progression in Rheumatoid Arthritis than Any Definition of Clinical Remission , 2015 .
[6] S. Norton,et al. OP0179 Different Levels of Moderate Disease in Rheumatoid Arthritis (RA) are Associated with Varying Risk for Joint Destruction and Failure. Time to Update Das Cut-Offs for Biologic Dmard Use? , 2015 .
[7] P. V. van Riel,et al. Personalizing Treatment Targets in Rheumatoid Arthritis by Using a Simple Prediction Model , 2015, The Journal of Rheumatology.
[8] C. Allaart,et al. A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study , 2014, The Journal of Rheumatology.
[9] K. Liao,et al. SAT0039 Development and Validation of A Prognostic Clinical Model for RAPID Radiographic Progression in Patients with RA , 2014 .
[10] E. Sasso,et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial , 2014, Annals of the rheumatic diseases.
[11] R. Westhovens,et al. The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA. , 2014, Seminars in arthritis and rheumatism.
[12] Arier C. Lee,et al. MRI osteitis predicts cartilage damage at the wrist in RA: a three-year prospective 3T MRI study examining cartilage damage , 2014, Arthritis Research & Therapy.
[13] R. Tsonaka,et al. Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors , 2014, Annals of the rheumatic diseases.
[14] E. Keystone,et al. Anticitrullinated Protein Antibodies and Rheumatoid Factor Fluctuate in Early Inflammatory Arthritis and Do Not Predict Clinical Outcomes , 2013, The Journal of Rheumatology.
[15] Matthias Schneider,et al. Rheumatoid arthritis--early diagnosis and disease management. , 2013, Deutsches Arzteblatt international.
[16] G. Cavet,et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study , 2012, Annals of the rheumatic diseases.
[17] Jinoos Yazdany,et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice , 2012, Arthritis care & research.
[18] I. González-Álvaro,et al. Interleukin 15 Levels in Serum May Predict a Severe Disease Course in Patients with Early Arthritis , 2011, PloS one.
[19] P. Kiely,et al. Outcome in rheumatoid arthritis patients with continued conventional therapy for moderate disease activity--the early RA network (ERAN). , 2011, Rheumatology.
[20] F. Wolfe,et al. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients , 2011, Arthritis care & research.
[21] Tsutomu Takeuchi,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.
[22] John Wong,et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.
[23] N. D. V. D. Amo,et al. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. , 2006 .
[24] M. Ahlmén,et al. The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. , 2004, The Journal of rheumatology.
[25] M. V. van Leeuwen,et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[26] R. Ionescu,et al. Original papers: clinical or basic research anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis , 2009, Journal of medicine and life.
[27] B. Combe,et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. , 1999, The Journal of rheumatology.